Archford Capital Strategies LLC Has $325,000 Stock Holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Archford Capital Strategies LLC decreased its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,462 shares of the company’s stock after selling 2,070 shares during the period. Archford Capital Strategies LLC owned 0.48% of Global X Genomics & Biotechnology ETF worth $325,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC bought a new position in shares of Global X Genomics & Biotechnology ETF in the 2nd quarter valued at about $590,000. Centaurus Financial Inc. acquired a new position in Global X Genomics & Biotechnology ETF in the second quarter valued at approximately $146,000. James J. Burns & Company LLC boosted its stake in Global X Genomics & Biotechnology ETF by 6.0% in the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after acquiring an additional 1,038 shares during the last quarter. Corrado Advisors LLC grew its holdings in Global X Genomics & Biotechnology ETF by 3.0% during the 3rd quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock worth $723,000 after acquiring an additional 1,894 shares during the period. Finally, Atria Investments Inc bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at $122,000. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Down 1.1 %

NASDAQ:GNOM opened at $10.18 on Monday. Global X Genomics & Biotechnology ETF has a 12-month low of $9.50 and a 12-month high of $12.53. The stock’s fifty day simple moving average is $10.14 and its 200-day simple moving average is $10.74. The firm has a market capitalization of $70.95 million, a P/E ratio of -4.35 and a beta of 1.03.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.